Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Eric P. Krenning, Ghassan El‐Haddad et al.|New England Journal of Medicine|2017Cited by 3.2k
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trialMichael J. Pishvaian, Emanuel F. Petricoin, Vincent Chung et al.|The Lancet Oncology|2020Cited by 541
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward M. Wolin, Beth Chasen et al.|Journal of Clinical Oncology|2018Cited by 388
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancerVivek Nimgaonkar, Eric A. Collisson, Viswesh Krishna et al.|Cell Reports Medicine|2023Cited by 19